ORALLY INHALED AND NASAL DRUG PRODUCTS SUBCOMMITTEE OF
THE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE
April 26, 2000
Briefing Information
FDA OINDP Working Groups List
ppt htmFederal Register Notice - April 26, 2000 Subcommittee Meeting
pdf txtOINDP Expert Panel Planning Meeting November 8, 1999 Minutes
AAPS Workshop on Regulatory Issues Related to Drug Products for Oral Inhalation and Nasal Delivery Slide Presentations:
FDA Nasal BA/BE Guidance Overview, Wallace P. Adams, Ph.D.
ppt htmPharmacodynamic Testing for Orally Inhaled Drugs: Corticosteroids, Staffan Edsbacker, PhD
ppt htmClinical Efficacy Testing for Nasal Drugs, Mary M. Fanning, Ph.D.
ppt htmClinical Efficacy Testing for Orally Inhaled Drugs, Robert Meyer, M.D.
ppt htmPharmacokinetic Testing for Systemic Exposure of Orally Inhaled and Nasal Drugs, Venkata Ramana Uppoor, M.Pharm., Ph.D., R.Ph.
ppt htmContent Uniformity for Inhalation Drug Products, Guirag Poochikian, Ph.D.
Adams WP, Singh GJP, Williams RL. Nasal Inhalation Aerosols and Metered Dose Spray Pumps: FDA Bioequivalence Issues, Program and Proceedings, Respiratory Drug Delivery VI, Interpharm Press, Buffalo Grove IL, 1998, pp. 219-25.
Comments for
Docket Number 99D-1738 Bioavilability & Bioequivalence Studies for Nasal Aerosols